Emergent BioSolutions, Inc., calls for continued fight against TB

Emergent BioSolutions, Inc., marked the observance of World Tuberculosis Day on Thursday by reminding the world that the fight against TB continues and that real progress has been made towards its elimination.

Two billion people, or one-third of the world’s population, are infected with the bacilli that cause TB. The World Health Organization has released estimates that there are nine million new cases and 1.7 million deaths from TB every year.

“One of the barriers identified towards eliminating TB is the lack of a fully effective vaccine in the market,” Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, Inc., said.

The title of the World TB Day 2011 campaign is "On the move against TB: Transforming the fight towards elimination.” Emergent BioSolutions, Inc.’s, goal is to move towards elimination of the disease through the development of a new TB vaccine.

"As a collaborator in the Oxford-Emergent TB Consortium, Emergent’s joint venture with the University of Oxford, to develop what could be the first new TB vaccine in 90 years, we are pleased to be working toward a solution to address this global health emergency," El-Hibri said.

Emergent BioSolutions, Inc., is currently in a Phase IIb clinical trial to evaluate the efficacy of MVA85A, the world’s most clinically advanced TB vaccine. In Worcester, South Africa, 2,784 infants are being administered the vaccine by the University of Cape Town’s South African Tuberculosis Vaccine Initiative, in partnership with OETC and the Aeras Global TB Foundation.